Denali Therapeutics Q4 2022 Earnings Report
Key Takeaways
Denali Therapeutics reported a net loss of $98.7 million for the fourth quarter of 2022, with collaboration revenue of $10.3 million and research and development expenses of $92.1 million. The company's cash, cash equivalents, and marketable securities were $1.34 billion as of December 31, 2022. Denali is focused on advancing its therapeutic portfolio and expanding its Transport Vehicle platform.
Denali transitioned to late-stage clinical development in therapeutic programs for Parkinson's, MPS II, and ALS.
The company expanded its Transport Vehicle (TV)-enabled portfolio with first-in-human studies in programs for FTD-GRN and Alzheimer’s.
DNL310, an investigational therapy for MPS II, showed positive changes in exploratory clinical outcomes and normalization of CSF heparan sulfate in an ongoing Phase 1/2 study.
Sanofi initiated a Phase 2 clinical trial in multiple sclerosis (MS) for SAR443820/DNL788, triggering a $25 million milestone payment to Denali.
Denali Therapeutics
Denali Therapeutics
Denali Therapeutics Revenue by Segment
Forward Guidance
Denali anticipates an increase of approximately 25-30% in cash operating expenses compared to 2022, partially offset by up to $50 million from incoming cash and milestone payments from Denali's current partnerships.